Loading...
Impact of pharmacotherapy on the incidence of transurethral prostatectomy for benign prostatic hyperplasia and the implications for surgical training.
Long, R Connolly, S Sweeney, P
Long, R
Connolly, S
Sweeney, P
Author
Advisors
Editors
Other Contributors
Date
2010-10
Date Submitted
Keywords
Other Subjects
Subject Mesh
5-alpha Reductase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Drug Utilization
Humans
Ireland
Male
Prostatic Hyperplasia
Retrospective Studies
Transurethral Resection of Prostate
Adrenergic alpha-1 Receptor Antagonists
Drug Utilization
Humans
Ireland
Male
Prostatic Hyperplasia
Retrospective Studies
Transurethral Resection of Prostate
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Article5643.pdf
Adobe PDF, 9 KB
Alternative Titles
Publisher
Abstract
Medical therapy has become first line treatment for Benign Prostatic Hypertrophy (BPH) and in many cases TURP may no longer be required. Proof and quantification of this evolution in practice has been somewhat elusive and provided the principle impetus for this study. This is a retrospective study of BPH management in Republic of Ireland from 1995 to 2008. National treatment databases were sourced for numbers undergoing TURP and pharmacotherapy prescribing data was obtained from individual pharmaceutical companies. A total of 28,240 TURP's were performed nationally between 1995 and 2008. TURP's performed annually, decreased by 1,494 (51%), alpha-blocker prescriptions increased from 8,710 to 302,159 units and the number of urology trainees increased by 10 (60%). Clear association between decreases in TURP's and increases in pharmacotherapy for BPH is demonstrated. Implications on training likely exist and will require proper evaluation in order to maintain future standards in this surgical practice.
Language
en
ISSN
0332-3102
eISSN
ISBN
DOI
PMID
21186754